Skip Navigation LinksHome > May 2014 - Volume 22 - Issue 3 > Ceftriaxone for Methicillin-Sensitive Staphylococcus aureus...
Infectious Diseases in Clinical Practice:
doi: 10.1097/IPC.0000000000000109
Review Articles

Ceftriaxone for Methicillin-Sensitive Staphylococcus aureus Osteoarticular Infections: A Survey of Infectious Disease Physicians’ Attitudes and Review of the Literature

Sharff, Katie A. MD*; Graber, Christopher J. MD; Spindel, Steven J. MD; Nguyen, Hien M. MD

Supplemental Author Material
Collapse Box


Abstract: The use of ceftriaxone for methicillin-sensitive Staphylococcus aureus (MSSA) osteoarticular infections in outpatient antimicrobial therapy remains controversial. Our informal survey of 135 academic and community infectious disease physicians suggests that only 96 (71.1%) are willing to use ceftriaxone for MSSA osteoarticular infections, 55 of which use it only infrequently (ie, 1%–19% of the time). Among the ceftriaxone users, most believe that there is a role for ceftriaxone in acute osteomyelitis (82.2%), chronic osteomyelitis (63.3%), osteomyelitis with uncomplicated bacteremia (61.1%), vertebral osteomyelitis (57.8%), and prosthetic infections (51.1%). We reviewed the clinical literature and analyzed ceftriaxone pharmacokinetics-pharmacodynamics to construct a clinical framework to optimally use ceftriaxone in osteoarticular infections. We conclude that ceftriaxone may be a reasonable therapeutic option for acute, uncomplicated MSSA osteoarticular infections after adequate surgical debridement, particularly when ceftriaxone is given as 2 g daily for MSSA isolates with oxacillin minimal inhibitory concentration values of 0.5 μg/mL or less (corresponding to ceftriaxone minimal inhibitory concentration values of ≤4 μg/mL).

© 2014 by Lippincott Williams & Wilkins.

Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.